What Happens If Seniors Take Eliquis Once a Day?

Eliquis (apixaban) is not approved or recommended as a once-daily medication for any patient, including seniors. The drug is prescribed twice a day for every condition it treats, whether that is stroke prevention in atrial fibrillation or treatment of blood clots. What does change for some older adults is the dose per tablet, from 5 mg down to 2.5 mg, but the twice-daily schedule stays the same. The confusion between a lower dose and a less frequent dose is common, and it matters more than many people realize.

Why Twice a Day Is Not Optional

The reason Eliquis must be taken every twelve hours comes down to how quickly your body clears the drug. Apixaban reaches its highest concentration in your blood about three to four hours after you swallow it, then steadily drops, with a half-life of roughly twelve hours.¹ That means by twelve hours after a dose, about half the drug is gone. If you skip the second dose and wait a full twenty-four hours, blood levels fall low enough that you may spend several hours of each day with inadequate protection against clots.

This is different from some other blood thinners in the same drug class. Rivaroxaban (Xarelto) and edoxaban (Savaysa), for example, are taken once daily for atrial fibrillation. Their chemistry allows them to maintain effective blood levels over a longer window. Apixaban simply does not work that way. The twice-daily schedule keeps drug levels in a steadier range throughout the day, avoiding the sharp peaks and deep troughs that a once-daily schedule would create.

When the Dose Goes Down but the Schedule Stays

This is where a lot of the confusion starts. Many seniors hear from their doctor that they qualify for the “lower dose” of Eliquis and assume that means taking it less often. In reality, the standard dose is 5 mg twice daily, and the reduced dose is 2.5 mg twice daily. The frequency never changes.

You qualify for the lower dose if you meet at least two of three criteria: you are 80 years or older, you weigh 60 kg (about 132 pounds) or less, or your serum creatinine is 1.5 mg/dL or higher.² All three of these factors cause apixaban to build up more in your system, so the lower dose compensates. But even with 2.5 mg tablets, you still take one in the morning and one in the evening.³

A separate situation arises with long-term prevention of recurring blood clots in the legs or lungs. After the initial treatment phase, the extended prevention dose of apixaban is also 2.5 mg twice daily.⁴ Again, twice daily.

Inappropriate Dosing Is Alarmingly Common

The distinction between dose reduction and frequency reduction is not just a technicality that patients get confused about. Doctors themselves get it wrong with surprising frequency. A study of older atrial fibrillation patients found that roughly 37% of those on newer oral anticoagulants were receiving inappropriate doses.⁵ A German registry tracking apixaban use in real clinical practice found inappropriate underdosing in about 22% of patients, most commonly in elderly patients with higher bleeding risk scores or a history of bleeding.⁶ That same registry noted that 1.6% of patients were on a once-daily 2.5 mg regimen, a dosing schedule that does not appear in any guideline.

Underdosing usually happens because a physician is nervous about bleeding risk and decides to lower the dose beyond what the label recommends. The intention is protective, but the effect can be the opposite: you lose clot protection without gaining meaningful safety. A retrospective analysis of elderly patients found that apixaban was initially dosed according to FDA recommendations in about 93% of cases, but maintaining correct dosing throughout treatment proved harder, with common reasons for drift including fluctuating kidney function and recommendations from other providers on the care team.⁷

Peak Levels and Bleeding Risk

One underappreciated advantage of twice-daily dosing is that it produces lower peak drug levels compared with cramming the same total amount into a single daily dose. Research on patients taking direct oral anticoagulants for atrial fibrillation has shown that those who experienced bleeding events tended to have higher peak drug concentrations than those who did not bleed.⁸ By splitting the dose across two administrations, apixaban keeps those peaks modest. If someone were to take a full day’s worth of apixaban in one shot, the peak would be substantially higher, and the trough before the next dose substantially lower, a pattern that increases bleeding risk at the top and stroke risk at the bottom.

This pharmacologic profile is actually one of the reasons apixaban tends to cause less gastrointestinal bleeding than some once-daily alternatives. A large study of Medicare beneficiaries aged 65 and older found that rivaroxaban, a once-daily drug, was associated with a higher rate of major hemorrhagic events compared with apixaban: roughly 7.5 versus 5.9 per 1,000 person-years.⁹ The same study also found rivaroxaban associated with higher rates of major ischemic events. Expert reviews of anticoagulant options for older adults have specifically recommended apixaban or edoxaban as preferable in this population because of their reduced major bleeding signals in clinical trials.¹⁰

Once-Daily Blood Thinners Do Exist, but They Are Not Eliquis

If you genuinely cannot manage twice-daily dosing, it is worth knowing that two other anticoagulants in the same class are dosed once daily for atrial fibrillation: rivaroxaban (Xarelto) and edoxaban (Savaysa). A post-hoc analysis of stroke patients enrolled in the ELAN trial compared outcomes between once-daily and twice-daily direct oral anticoagulants and found no clear difference in the combined rate of recurrent stroke, systemic embolism, major bleeding, or vascular death over 90 days.¹¹ That sounds reassuring for once-daily options, but the study was not specifically designed to test this comparison, and the authors acknowledged significant limitations.

The choice between these drugs is not just about convenience. As the Medicare data showed, rivaroxaban carried higher rates of both bleeding and ischemic events in older adults compared with apixaban.¹² Edoxaban fared better on bleeding in clinical trials, but it is far less commonly prescribed in many countries and may not be on your insurance formulary. In other words, the trade-off for switching to a once-daily drug may be a measurably higher risk of serious complications, not simply a matter of swapping one equivalent pill for another.

Kidney Function Changes Everything for Seniors

Your kidneys clear about a quarter of each apixaban dose, and kidney function naturally declines with age. This matters because as the kidneys slow down, apixaban lingers longer in the blood, effectively raising its concentration even if you are taking the same dose. Research has shown that compared with patients who have normal kidney function, apixaban exposure increases by about 16% in mild kidney impairment, 29% in moderate impairment, and 38% in severe impairment.¹³

A study of older hospitalized patients found even more dramatic differences in real-world conditions: patients with severely reduced kidney filtration had dose-adjusted apixaban blood levels more than three times higher than patients with normal function.¹⁴ These are not abstract numbers. Higher drug levels correlate with bleeding, and lower kidney function is common in seniors. It is one reason the dose reduction criteria include serum creatinine.

Pharmacokinetic modeling has suggested that healthy elderly adults might need doses reduced to roughly 70% of the standard adult dose to achieve the same drug exposure, and that elderly patients with moderate or severe kidney impairment may need further reductions beyond that.¹⁵ The current label criteria, the two-of-three rule described earlier, are a simplified version of this reality. They work for most patients, but they are blunt instruments. If your kidney function is borderline or fluctuating, your doctor may need to recheck your labs periodically to make sure you are still on the right dose.

Why Twice-Daily Dosing Is Harder Than It Sounds

It is easy for a younger person to say “just take it twice a day.” In practice, sticking to a twelve-hour dosing schedule is one of the most common challenges older adults face with apixaban. A qualitative study of elderly outpatients managing multiple medications found that adherence was less than perfect in nearly half of participants, and the interviews revealed a particularly troubling pattern: the medication management strategies people relied on gradually broke down as they aged and experienced cognitive changes, often without the person realizing it.¹⁶

This is where the appeal of once-daily dosing becomes understandable. One pill a day is objectively easier to remember than two. But with apixaban, skipping to once daily is not a sanctioned shortcut; it is an underdose that leaves you partially unprotected. If adherence is genuinely difficult, there are some practical strategies worth discussing with your doctor or pharmacist:

Pill organizers: A weekly organizer with separate morning and evening compartments can make it visually obvious whether you have taken your dose. Some organizers offer three compartments per day for people on complex medication regimens.
Phone alarms or apps: Setting two daily alarms twelve hours apart is simple and effective. Some pharmacy apps also send push notifications.
Anchoring to meals: Taking apixaban with breakfast and dinner creates a routine tied to an activity you already do. The drug can be taken with or without food.
Caregiver involvement: If memory is a concern, having a family member or home health aide supervise the evening dose can catch the gaps that self-managed systems miss.

The German registry data found that about 89% of apixaban patients were still on the drug after one year, which is reasonably good compared with other anticoagulants.¹⁷ But persistence with the medication is not the same thing as taking every dose correctly. You can refill your prescription on time and still miss enough evening doses to chip away at your protection.

What to Do If You Miss a Dose

The manufacturer’s guidance is straightforward: if you miss a dose, take it as soon as you remember, then resume your regular schedule. If it is already close to the time of your next dose, skip the missed one and take your next dose at the usual time. Never double up to make up for a missed dose. “Close to the next dose” is generally interpreted as within about six hours of the next scheduled dose, though your prescriber may give you more specific instructions based on your situation.

What is important to understand is that an occasional missed dose, while not ideal, is far less dangerous than systematically taking the drug once daily. One missed dose means a few hours of reduced protection. Chronic once-daily dosing means every single day includes a long stretch where drug levels have dropped below the effective range. The cumulative stroke risk from that pattern is meaningfully higher than from the occasional slip.

The Cost Problem Behind the Question

Sometimes the question about once-daily dosing is really a question about cost. Taking a medication twice daily means going through twice as many tablets, and Eliquis is not cheap. An analysis of formulary drug tiers found Eliquis positioned in higher cost tiers with monthly out-of-pocket costs around $154, adding up to over $1,800 per year.¹⁸ For seniors on fixed incomes, that is a significant expense, and the temptation to stretch pills by taking one a day instead of two is real.

If cost is the barrier, stretching your pills is the wrong solution. A better approach is to ask your doctor’s office about manufacturer copay assistance programs, check whether your Medicare Part D plan places the generic version (apixaban became available as a generic in some markets) at a lower tier, or discuss with your prescriber whether a switch to a different anticoagulant that may be more affordable on your specific plan is appropriate. Some patients on warfarin, the old-fashioned blood thinner that requires regular blood monitoring, pay a fraction of what Eliquis costs. Warfarin has its own drawbacks for elderly patients, including more drug and food interactions and the need for frequent lab visits, but for some people the trade-off is worth having.

When Dose Adjustments Get Complicated

The two-of-three criteria for reducing the apixaban dose seem simple on paper, but in older adults, the variables they depend on can shift. Weight fluctuates with illness, appetite changes, and fluid retention. Creatinine levels bounce around with hydration status, acute illness, and new medications. A patient who qualified for the full 5 mg dose at their last checkup might now meet criteria for 2.5 mg, or vice versa. The retrospective analysis of elderly patients on anticoagulants found that the most common reasons for drifting away from recommended dosing were exactly these fluctuations in estimated kidney function and dose changes recommended by other specialists on the care team.¹⁹

This is not an argument against apixaban. It is an argument for regular follow-up. If you are over 75 and taking Eliquis, periodic lab work to check kidney function and periodic weight checks are not optional extras. They are part of safe anticoagulant management. If your numbers change, your dose might need to change with them, and your doctor should be the one making that call rather than you adjusting on your own.

How Aging Itself Changes Drug Behavior

Beyond the specific dose reduction criteria, the aging body handles apixaban differently in ways that are harder to capture with a simple checklist. Liver metabolism slows, body composition shifts toward more fat and less water, and protein binding can change. Pharmacokinetic modeling has attempted to quantify these effects across different elderly subgroups, including those with various degrees of kidney and liver impairment. The modeling suggested that even a healthy elderly person without kidney or liver disease may need a dose roughly 30% lower than a healthy younger adult to achieve the same drug exposure.²⁰ The current label does not account for age alone as a reason to reduce the dose unless the patient also meets one of the other criteria, which means some older adults may be getting more drug exposure than expected without technically qualifying for the reduced dose.

This is an area of active discussion in cardiology and geriatric medicine. Some clinicians argue that the dose reduction criteria should be broadened for very elderly patients, while others worry that further dose reductions would leave patients underprotected against stroke. For now, the official guidance has not changed, but it is worth understanding that the “right” dose for a 85-year-old who weighs 70 kg and has normal creatinine is probably not delivering the same drug exposure it would in a 55-year-old with identical lab values. Whether that difference is clinically meaningful enough to warrant a label change remains an open question.

Talking to Your Doctor About Dosing Concerns

If you have been thinking about taking Eliquis once a day, whether because of convenience, cost, or a vague memory that your neighbor takes their blood thinner once daily, the most productive thing you can do is bring it up directly with your prescriber. There is no shame in the question, and doctors who work with older adults hear it regularly. What you want to walk away from that conversation understanding is that the frequency is non-negotiable with this particular drug, but the dose can and should be tailored to your body. If adherence to twice-daily dosing is genuinely beyond what you can manage, your doctor can discuss whether a once-daily anticoagulant might be a reasonable alternative for your specific risk profile, or whether adding adherence tools could solve the problem without changing the medication. The worst outcome is quietly halving your dose without telling anyone and spending months partially unprotected against a stroke that the drug, taken correctly, could have prevented.